The value proposition in contemporary health and disease care (IMAGE)

Elsevier

The value proposition in contemporary health and disease care

Caption

The value proposition in contemporary health and disease care: A study published in the Canadian Journal of Cardiology into the cost-effectiveness of the use of semaglutide in overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, shows that semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, but can be in the long-term with price reductions or rebates.

Credit

James Stone/Ana Johnson, Canadian Journal of Cardiology

Usage Restrictions

Please include attribution

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.